About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The last week of February features plenty of key earnings reports, as well as some delayed economic data and speeches from several Federal Reserve officials. Wall Street will also be eyeing key inflation data in the form of the the producer price index (PPI) for January.On the earnings front, Domino's Pizza (DPZ), C3.ai (AI), CoreWeave (CRWV), Dell Technologies (DELL), Hims & Hers Health (HIMS), Home Depot (HD), IonQ (IONQ), Lucid Group (LCID), Lowe's (LOW), HP (HPQ) Mosaic (MOS), MP Materials (MP), Nvidia  ...

Key Takeaways Hims & Hers is set to post Q4 2025 results, with revenue projected to rise 28.7% year over year.Hims & Hers expanded into low testosterone, menopause care and Labs, boosting subscriber growth.HIMS faces higher marketing and operating costs plus compounded semaglutide legal scrutiny from Novo Nordisk.Hims & Hers Health, Inc. (HIMS) is scheduled to report fourth-quarter 2025 results on Feb. 23, after the closing bell.In the last reported quarter, the company’s earnings per share (EPS) of 6 cents ...

Core Viewpoint - Hims & Hers Health Inc is facing significant challenges, with its stock near 17-month lows despite a recent acquisition of Eucalyptus for $1.15 billion and plans for global expansion [1][2]. Group 1: Stock Performance - Shares of Hims & Hers Health have experienced volatile performance, dropping 90% from a record high of $72.98 on February 19, and currently trading at $15.91 [1][2]. - The stock has only seen two gains in the last 14 trading sessions, indicating a prolonged period of underperformance [2]. Group 2: Market Indicators - The stock's 14-day Relative Strength Index (RSI) is at 10.2, indicating it is deeply in "oversold" territory, suggesting a potential for a short-term bounce [2]. - Short interest in Hims & Hers Health has increased by 14.4% over the past two reporting periods, now representing approximately 37.5% of the stock's available float [3].

Hims & Hers Looks to Expand Globally With Buy of Australian Telehealth Provider - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers to Buy Australian Telehealth Provider Eucalyptus in $1.15 Billion DealBy [Mackenzie Tatananni]ShareR ...

Core Insights - Hims & Hers Health, Inc. (HIMS) has experienced a significant decline of approximately 50% year-to-date, marking a continuous downward trend since the initial coverage began [1] Company Performance - The stock has dropped 50% since the first coverage, indicating a persistent negative momentum in its market performance [1] Analyst Background - The analysis is provided by a retired Wall Street portfolio manager with over two decades of experience in the technology, media, and telecommunications (TMT) sectors, emphasizing a focus on risk mitigation and momentum strategies [1]

The positive movement follows the announcement of a definitive agreement to acquire Eucalyptus, a digital health leader, which is expected to enhance Hims & Hers’ international presence.Hims & Hers agreed to acquire Eucalyptus, which operates in multiple countries, including Australia, the U.K., and Germany.The deal is structured to maintain financial flexibility, with the company planning to finance most of the transaction using existing cash and future operating cash flows.Deal ConsiderationThe transactio ...

Core Viewpoint - Hims & Hers Health shares experienced a rally following the announcement of a deal to acquire an Australia-based telehealth provider [1] Company Summary - Hims & Hers Health is expanding its services through the acquisition of a telehealth provider based in Australia [1] Industry Summary - The health-and-wellness sector is seeing increased consolidation as companies seek to enhance their telehealth offerings [1]

根据交易条款，交易完成后Hims需支付近2.4亿美元现金。Eucalyptus还可在未来18个月内获得递延业绩 对价，并有望在2029年初前根据财务目标完成情况收取额外款项。 Hims可选择以现金或股票形式支付大部分递延及业绩对价。 智通财经APP获悉，Hims & Hers Health(HIMS.US)宣布将以现金加股票的方式收购澳大利亚数字健康服 务商Eucalyptus，交易价值最高可达11.5亿美元。受此消息提振，该公司股价周四美股盘前上涨约7%。 总部位于悉尼的Eucalyptus年营收规模超4.5亿美元，是澳大利亚规模最大的数字健康服务商。Hims预 计，此次收购将助力其拓展澳大利亚与日本市场，并进一步扩大在英国、德国和加拿大的业务布局。 据了解，总部位于美国加州旧金山的Hims主营减重药物复方制剂销售，预计本次交易资金主要来自公 司现有现金及美国业务的运营现金流。该交易预计于2026年年中完成。 ...

Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth ProviderBy [Mackenzie Tat ...